Mucinex

(Guaifenesin)

ApprovedSmall molecule

RReckitt Benckiser LLC

Mucinex is one of 113 small molecule programs targeting Acute bronchitis. It is currently in Approved.

Indications

Total Trials

Active Trials

112

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

Acute BronchitisActive, not recruiting

PneumoniaActive, not recruiting

Back PainActive, not recruiting

Ovulation InductionCompleted

SinusitisCompleted

Acute BronchitisPreclinical

Active, not recruiting

PneumoniaPreclinical

Active, not recruiting

Back PainPreclinical

Active, not recruiting

Ovulation InductionPreclinical

Completed

SinusitisApproved

Completed

Competition

Competitive Landscape

155 competitors in Pneumonia

#DrugCompanyPhaseTrials

Mucinex

RReckitt Benckiser LLC

Approved

1 2

Jakafi

Incyte

Preclinical

1 3

Primaquine

Sanofi

Preclinical

1 4

Acanya

Pfizer

Preclinical

1 5

Prevacid

Takeda

Preclinical

1 6

Avlosulfon

AAlmirall, S.A.

Preclinical

4 7

Retrovir

BBp Consulting, Inc

Preclinical

2 8

Primsol

CConrado Roberto Hoffmann Filho

Preclinical

2 9

Virazole

CConrado Roberto Hoffmann Filho

Preclinical

2 10

Advil

KKenvue Brands

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Respiratory tract infection2 trials

Safety and Efficacy of Mucinex and IR Guaifenesin the Treatment of Symptoms of Acute Upper Respiratory Tract Infections

Completed·RReckitt Benckiser LLC·Phase 2/3·NCT01537081·2,810 enrolled

Study of Count Coughs in Subjects With Acute Upper Respiratory Tract Infections

Completed· Pfizer logo

Pfizer·N/A·NCT01062256·265 enrolled

Acute bronchitis1 trial

A Safety Study of Balsamic Bactrim in Pediatric Participants With Acute Bronchitis

Completed· Roche logo

Roche··NCT02879981·51 enrolled

Safety and Efficacy1 trial

Safety and Efficacy Study of Guaifenesin and Pseudoephedrine for Symptomatic Therapy to Treat Acute RTI

Completed·RReckitt Benckiser LLC·Phase 4·NCT01202279·1,179 enrolled

ALS1 trial

A Non-Interventional Safety Study of Balsamic Bactrim

Completed· Roche logo

Roche··NCT02902640·52 enrolled

Pneumonia1 trial

Effectiveness Study of Integrative Treatment for Pediatric Pneumonia

Completed·LLiaoning University of Traditional Chinese Medicine·N/A·NCT02069665·451 enrolled

7 more indications

Pediatric Patients1 trial

Comparative Efficacy of the Suppository Versus Guaiacol Suppository Versus Guaifenesin Syrup in Pediatric Patients With Cough Due the Infectious Origin

Unknown status·AAzidus Brasil·Phase 3·NCT01119534·270 enrolled

Back pain1 trial

Exploratory Efficacy Study of Guaifenesin in Upper Back Pain

Completed· GSK logo

GSK·N/A·NCT01562548·78 enrolled

Rhinitis1 trial

The Effect of Oral Guaifenesin on Pediatric Chronic Rhinitis: A Pilot Study

Completed·VVirginia Commonwealth University·Phase 2·NCT01364467·30 enrolled

Infections1 trial

Preventing Frequent Sinus Infections in HIV-Infected Patients

Withdrawn·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00000752

Ovulation Induction1 trial

Vaginal Estradiol and Oral Guaifenesin in Clomiphene Ovulation Induction

Completed·YYuzuncu Yil University·N/A·NCT07398924·90 enrolled

Sinusitis1 trial

Treatment of Acute Sinusitis

Completed·WWashington University School of Medicine·Phase 4·NCT00377403·172 enrolled

Unspecified1 trial

Mucinex Exploratory Cold Study

Completed·RReckitt Benckiser LLC·Phase 2·NCT01046136·378 enrolled

Regulatory

FDA Approval Timeline[4]

Dec 18, 2002

MUCINEX

NDA NDA021282

Sources

References

[1]
ClinicalTrials.gov — 13 trial records for Guaifenesin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Guaifenesin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Guaifenesin. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA021282). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Reckitt Benckiser LLC company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: RReckitt Benckiser LLC

Mucinex

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Respiratory tract infection2 trials

Acute bronchitis1 trial

Safety and Efficacy1 trial

ALS1 trial

Pneumonia1 trial

Pediatric Patients1 trial

Back pain1 trial

Rhinitis1 trial

Infections1 trial

Ovulation Induction1 trial

Sinusitis1 trial

Unspecified1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News